25 / 61
Notes:
Volume10, Issue 12 (Suppl)
J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 81
conferenceseries
.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20
th
International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9
th
WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Serum EGF in non-small cell lung cancer: The biomarker value & the role of platelets
Idania González Pérez
Center of Molecular Immunology, Cuba
Background:
The CIMAvax-EGF® is a promising Cuban therapeutic vaccine for advanced non-small cell lung cancer (NSCLC),
targeted to the potent mitogen epidermal growth factor (EGF). Retrospective studies of serum EGF concentrations ([sEGF])
in NSCLC patients treated with this vaccine, have revealed the predictive value of the sEGF levels for this immunotherapy.
However, its putative diagnostic value, although studied is not conclusive because of the lack of standardized methodologies
for quantitation. This study was aimed first at the estimation of the possible diagnostic value of [sEGF], using a previously
standardized quantification procedure, controlling the crucial factors that influence [sEGF].
Methods:
The [sEGF] of 25 patients were determined by ELISA, before/after the first-line-therapy, in sera collected 1h and 4h
after phlebotomy. The contribution of platelets was considered analyzing their counts and through the normalization of some
other variables by platelets counts.
Results:
The variables [EGF]1h, [EGF]4h and [EGF]4h/platelets/L were not discriminatory (AUC=0.6464, p=0.07590;
AUC=0.5267, p=0.7490 and AUC=0.6125, p=0.2424, respectively). There were significant differences between patients and
controls by variables r=[EGF]4h/[EGF]
1h
(AUC=0.7075, p=0.01281), d=[EGF]
4h
-[EGF]
1h
(AUC=0.6962, p=0.02038), Platelets/L
(AUC=0.8253, p=0.0006588), [EGF]
1h
/platelets/L (AUC=0.7440, p=0.01061), and d/platelets/L (AUC=0.8653, p=0.0001487).
Conclusions:
The absolute [sEGF] had no diagnostic capacity, which was better achieved by variables normalized by platelet
counts. The comprehension of the role of platelets in the measured EGF levels should allow a better interpretation of the
assessed values, to judge about the dependence of the tumors from EGF. This knowledge should also impact the clinical
management of patients and the individualization of their therapies.
Biography
Idania González Pérez has completed her BSc in Physics from the Faculty of Physics, Moscow State University, Russia (1985-1990) and Master of Science in
Physics and Mathematics from Faculty of Physics, Moscow State University, Russia. She is now involved in a PhD program at the University School of Medicine in
Havana. She is a Senior Researcher at the Center for Molecular Immunology in Havana, Systems Biology Department, Biomarkers Group. She has published more
than 15 papers in reputed journals and has been serving as a Reviewer in Medical Science Monitor, Journal of Hospital and Clinical Pharmacy and International
Blood Research & Reviews.
idaniagp@cim.sld.cuIdania González Pérez, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110